Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone vs losartan for mild to moderate primary hypertension
CTR20191434Phase 3Completed
- Sponsor
- Nanjing Cavendish
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eplerenone in essential hypertension, left ventricular systolic dysfunction (LVSD), heart failure (HF), myocardial infarction (MI), sponsored by Nanjing Cavendish. Started Oct 2019; status: completed.
02
Drugs
eplerenone
03
Conditions
essential hypertensionleft ventricular systolic dysfunction (LVSD)heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20191434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191434.